What Statum Treats: Main Uses and Benefits

The therapeutic domain of Statum is generally associated with the management of yeast and fungal infections of the skin and vagina, reflecting its intended use.

Statum is commonly used to help with localized skin conditions caused by fungal organisms, including Ringworm, Athlete's Foot, Jock Itch, alongside specific types of cutaneous candidiasis and Vulvovaginal Candidiasis. It is applied in scenarios where additional management of discomfort is required for symptoms that cluster into patterns of intense itching, redness, scaling, and skin cracking or fissuring. This application contributes to easing the overall symptom load and supports general well-being during symptomatic phases.

“This therapeutic agent plays a role in managing symptoms that become more disruptive during flare-ups of fungal overgrowth.”

---

Quick Fact: Supportive Symptomatic Management

Property	Description
Main Conditions	Tinea infections, Cutaneous Candidiasis, Vulvovaginal Candidiasis
Symptom Focus	Itching, Burning, Redness, Scaling
Patient-Oriented Benefit	Easing overall symptom burden, maintaining functional stability
Context	Conditions involving episodic or fluctuating manifestations

Eligibility Map: Who can and cannot use Statum (Clotrimazol) — Official Regulatory Information

Populations for whom use is contraindicated:

• Patients with known hypersensitivity or allergy to the active substance, Clotrimazol, or to any of the product’s inactive ingredients (excipients).

Eligibility-Related Restrictions:

• Use is restricted to superficial fungal infections of the skin or vagina; the medicine is not established for treating deep or systemic infections.

Population Group	Eligibility Status (as per regulatory labels)
Adults (18+ years)	Generally Eligible for labeled topical and vaginal use.
Children under 12 years	Use is often not established or not recommended for certain internal uses.
Pregnancy	Generally Acceptable (often with caution); minimal systemic absorption is documented.
Lactation (Breastfeeding)	Generally Acceptable; negligible transfer to breast milk is expected due to low systemic absorption.
Renal/Hepatic Impairment	No specific restriction is typically documented, reflecting minimal systemic exposure.

---

Official Eligibility Statements:

• The use of Statum is contraindicated in patients with a history of allergic reaction to Clotrimazol or its components.
• Use is generally established for adults for approved indications, and often acceptable for adolescents (12–17 years) under specific instructions.
• The regulatory classification defines use during pregnancy and lactation as generally acceptable, given the localized application route.

Connection to the overall eligibility profile: Regulatory documents define eligibility primarily by establishing an absolute non-eligibility for individuals with known hypersensitivity to the drug. Beyond this restriction, eligibility for Statum is largely defined by age limitations, particularly setting a threshold for internal use in children, and by confirming acceptable status during reproductive periods (pregnancy and lactation) due to the drug’s minimal systemic exposure.

Interactions with other medicines and products

The official regulatory profile for Statum (Clotrimazol, Topical/Vaginal) documents interactions arising from its minimal systemic absorption and direct physical effects.

Interaction Scope	Official Regulatory Information
Medicinal products with documented interactions	Immunosuppressants; Latex-containing Barrier Contraceptives
Specific interacting medicines	Tacrolimus, Sirolimus
Mechanistic basis of interactions	Pharmacokinetic (potential enzyme inhibition); Physical/Chemical (Material integrity damage)
Timing-based interaction rules	Alternative contraceptive precautions must be used for at least five days following the vaginal administration.

The most commonly documented interaction is a physical one: the product can cause damage to latex contraceptives (such as condoms and diaphragms), which leads to reduced effectiveness.

Concomitant vaginal use may also lead to a pharmacokinetic interaction with certain immunosuppressants. The vaginal administration may result in minimal systemic absorption that can potentially increase the plasma concentrations of Tacrolimus and Sirolimus, necessitating close monitoring.

Interaction Classifications (High-Level): These are classified as clinically significant interactions that require monitoring or the use of alternative precautions, as defined in regulatory documents like the European Summary of Product Characteristics and US FDA Prescribing Information. The official documentation states that no known interactions are documented for the topical or vaginal formulations with food, alcohol, herbal products, or supplements.

How Statum Works

Clotrimazol, the active component of Statum, exerts its action through the selective inhibition of a key fungal enzyme, Lanosterol 14-alpha demethylase (CYP51). This enzyme is crucial for the Ergosterol Biosynthesis Pathway, which is necessary for the construction of the fungal cell membrane. The drug acts as an inhibitor, preventing the conversion of lanosterol into ergosterol.

The resulting depletion of ergosterol and simultaneous accumulation of toxic methyl-sterols compromise the structural integrity of the fungal cell membrane. This compromise dramatically increases membrane permeability , leading to the rapid leakage of vital intracellular contents. This physiological breakdown results in both the fungistatic (growth-stopping) and fungicidal (cell-killing) effects, which result in the elimination of the fungal organism. The fungicidal action is highly concentration-dependent, requiring adequate local presence of the inhibitor to cause profound, irreversible structural damage, physiologically constraining its effectiveness in areas with limited penetration.

How to Use Statum: Official Administration Guidelines

Statum, containing the active substance Clotrimazol, is approved for use via localized application routes. Its official administration is defined by specific dosage forms corresponding to the target site: topical (creams, solutions), vaginal (tablets, creams), and transmucosal (oral lozenges for oropharyngeal use).

---

Official Dosing Regimens and Frequency

The required dosing schedule and frequency are strictly set by regulatory labeling. Topical dermal preparations are typically designated for application twice daily for a course duration that can range from two to four weeks. In contrast, vaginal preparations follow fixed-course regimens, which include administering 100 mg tablets for seven consecutive days, 200 mg tablets for three days, or a single 500 mg dose. These regimens are generally administered once daily.

Procedural and Contextual Conditions

Administration involves specific instructions detailed in the regulatory documents. Vaginal products are typically used at bedtime to promote optimal retention. Topical application requires the product to be gently rubbed into the entire affected area. For the oral lozenge form, the product must be allowed to dissolve slowly in the mouth and must not be chewed or swallowed whole. Use of vaginal forms is not recommended during the menstrual period, and age-group rules generally restrict topical use to children 2 years and older.

Use Protocol Summary

Regulatory instructions establish a sequential protocol that links the administration route to a fixed-duration course and a strict frequency pattern. The protocol mandates that the patient must complete the specific multi-day or single-day regimen defined by the label, ensuring consistent application over the entire scheduled period.

Research Evidence: Overview of Studies for Statum (Clotrimazol)

This section provides a descriptive summary of the official clinical research base for Statum's active ingredient, Clotrimazol. The information focuses only on the types of studies conducted, the outcomes they measured, and areas of established evidence versus uncertainty. This is a descriptive overview, and it does not contain advice, instructions, or recommendations for use.

Evidence for Vulvovaginal Candidiasis (VVC) Studies

Research for VVC has largely involved Randomized Controlled Trials (RCTs) and comprehensive meta-analyses. Studies were designed to monitor outcomes related to physical discomfort. They focused on the Mycological Cure Rate (fungal elimination) and the Clinical Cure Rate (assessment of symptom changes). Trials examined regimens of various lengths (e.g., single-dose, 3-day, 7-day) in research exploring short-term symptom changes in adult women. Systematic reviews and meta-analyses reported on the frequency of measured outcomes when comparing the active ingredient with other agents.

Evidence for Cutaneous Mycoses (Skin Infections)

Evidence for Statum's topical use includes numerous Double-Blind, Multicentric Trials for skin conditions like Athlete's Foot and Ringworm. These trials examined Mycological Cure and Clinical Improvement rate, which monitored the evolution of symptoms like scaling and redness. Evidence collected over decades describes patterns related to short-term mycological clearance and changes in symptoms measured during the study period across the studied skin infections.

Long-Term Follow-up and Durability of Response

Most primary clinical studies focused on acute infection and utilized limited follow-up durations (typically weeks) for initial cure assessment. Therefore, there is limited information for long-term outcomes. Research exploring recurrent VVC monitored recurrence over intervals up to six months. Findings from these trials describe patterns related to monitored changes in the frequency of symptomatic episodes, but the long-term effects are not fully established concerning the prevention of future recurrence.

What Remains Uncertain in the Research Landscape

Although Statum has been extensively researched, evidence highlights what is known—and what is still uncertain. Because follow-up durations were limited in many pivotal trials, there is limited information for long-term outcomes. The evidence quality varies across studies, and comparative evidence is lacking against the newest classes of topical antifungal drugs. Data for infections caused by fungal species other than Candida albicans and outcomes in patients with recurrent or complicated VVC are still emerging. Research provides context but not individual predictions, and study results reflect the specific conditions under which they were conducted.

Key Studies & References

1. Antifungal (oral and vaginal) therapy for recurrent vulvovaginal candidiasis: a systematic review and meta-analysis
2. USE OF CLOTRIMAZOLE IN PREGNANCY - UKTIS Monograph
3. Clotrimazole - StatPearls (Cutaneous Mycoses and General Monograph)
4. Label: CLOTRIMAZOLE 1% - clotrimazole cream (Topical OTC Monograph)

Common questions about Statum (FAQ)

Q: What are the most commonly reported side effects of Statum?

A: Official product information describes documented adverse reactions primarily related to the application site. These localized effects most frequently include a burning sensation, stinging, itching, redness (erythema), or irritation of the skin where the product was used.

---

Q: What should I know about stopping Statum treatment?

A: Regulatory guidance emphasizes that the medicine should be used for the full treatment course defined on the product label. The caution against stopping treatment early is based on the potential for the fungal infection to return.

---

Q: Is it possible for Statum to lose effectiveness over time?

A: The regulatory label addresses the possibility of the drug not providing expected relief. Official instructions advise the patient to stop use and consult a healthcare provider if there is no improvement after a specific period of time, such as four weeks for certain infections.

---

Q: Is Statum a generic drug?

A: Statum is the brand designation for the active ingredient Clotrimazol. Clotrimazol itself is classified as an established Monograph Drug, meaning non-branded, generic products containing the same active ingredient are widely available.

---

Q: What is the difference between Statum and its generic version?

A: Regulatory documents confirm that both the branded product, Statum, and its generic versions contain the same active substance, Clotrimazol. The non-active ingredients used in the formulation may vary between products.

---

Q: What is the maximum duration of use for Statum?

A: Official directions provide fixed treatment durations for each specific use. The label does not specify a maximum cumulative duration over time, but recommends consulting a healthcare professional if the condition persists beyond the recommended duration for that specific application.

---

Q: Is Statum used for any other conditions besides the main one?

A: In addition to vulvovaginal candidiasis, official regulatory documents list other common fungal infections as labeled uses. These often include athlete’s foot (tinea pedis), jock itch (tinea cruris), and ringworm (tinea corporis).

---

Q: How long does it typically take to see the effects of Statum?

A: Specific onset times are not provided in the general product information. However, official documents describe a timeframe after which consulting a healthcare professional is recommended if no improvement is observed, such as two to four weeks, depending on the type of infection being addressed.

---

Q: Does Statum have a 'build-up' period in the body?

A: Due to this medication being designed for localized application to the skin or vagina, its regulatory profile indicates that systemic absorption into the rest of the body is minimal. The drug works primarily by concentrating its effect directly at the infection site.

---

Q: Is it safe to drink alcohol in moderation while using Statum?

A: Official regulatory documents and safety profiles for the localized forms of this medication do not document any known interactions between the active substance, Clotrimazol, and the consumption of alcohol.

---

Q: Can Statum affect my ability to drive or operate machinery?

A: Official product documentation states that the active substance, Clotrimazol, has no or negligible influence on a person's ability to drive or use machinery. This is expected given the drug's localized application and minimal absorption.

---

Q: Can Statum be crushed, split, or chewed?

A: Instructions for certain solid dosage forms, such as oral lozenges, specifically mandate that the product must be allowed to dissolve slowly in the mouth and not be chewed or swallowed whole. Other dosage forms are intended to be used exactly as supplied on the product label.

---

Q: Is Statum known to cause weight gain?

A: Weight changes are not listed among the common or serious adverse reactions documented in the official regulatory safety profile for this localized medication.

---

Q: Can Statum affect my sleep?

A: Sleep-related changes, such as insomnia or drowsiness, are not listed in the common or serious adverse reactions documented in the official regulatory safety profile for this localized medication.

---

Q: Can Statum be taken by people with kidney problems?

A: Due to the drug’s localized use and minimal systemic absorption, regulatory documents typically indicate that no specific dosage adjustment or restriction is typically documented for individuals with kidney impairment.

---

Q: Is Statum suitable for people with liver conditions?

A: Due to the medicine's localized application route, regulatory information generally indicates that no specific dosage adjustment or restriction is typically documented for individuals with liver impairment.

---

Q: Does Statum affect blood pressure?

A: While not a common effect, regulatory information indicates that low blood pressure (hypotension) has been documented in rare cases as an adverse effect. These occurrences are usually reported in connection with more serious allergic or systemic reactions to the drug.

---

Q: Does Statum cause dry mouth?

A: Dry mouth is not listed among the common or serious adverse reactions documented in the official regulatory safety profile for this localized medication.

---

Q: What happens when Statum is taken with grapefruit juice?

A: Official regulatory documents do not document any known interactions between the localized use of the active substance and food or beverages, and this includes specific fruit juices like grapefruit juice.

---

Q: Are there different forms or strengths of Statum available?

A: Yes, the product is available in different dosage forms, such as creams, solutions, and pessaries (vaginal tablets), tailored for specific application sites. It is also available in different strengths (e.g., 1% or 2% formulations) depending on the intended use.

---

Q: Can Statum affect mood or mental state?

A: Changes in mood or mental state are not listed among the common or serious adverse reactions documented in the official regulatory safety profile for this localized medication.

How to Store and Dispose of Statum (Clotrimazol)

Statum must be stored at controlled room temperature, typically between 20 C and 25 C (68 F and 77 F). The regulatory guidance permits brief excursions up to 30 C.

The medication should be kept in its original container, with the lid tightly closed, and stored away from excess heat and moisture; therefore, it should not be kept in the bathroom. Certain formulations also require protection from light.

It is a mandatory requirement to keep Statum out of the reach and sight of children at all times.

For disposal, unused or expired product must be discarded in accordance with local regulations for pharmaceutical waste. Disposal into wastewater is generally advised against.